Global expansion ADVANZ PHARMA has a broad international footprint with commercial sales in over 90 countries and direct presence in more than 20 countries, presenting opportunities to expand partnerships, distribution agreements, and co-marketing initiatives in Europe, Canada, Australia, and the US.

Biosimilars & specialty focus The company actively develops and markets biosimilars and specialty medicines across therapeutic areas such as hepatology, gastroenterology, anti-infectives, CNS, and rare diseases, enabling cross-sell potential with collaborators in generic and biosimilar pipelines and hospital-focused procurement channels.

Strategic partnerships Recent and ongoing partnerships with HAL Allergy, Altamira, Attain Med, and Veeva Systems indicate a readiness to form co-development, distribution, and digital-modernization deals, offering selling opportunities through alliance-driven access and integrated CRM-driven initiatives.

Commercial modernization Adoption of Veeva Systems and a digital-first commercial foundation signals a shift toward modernized sales and marketing processes, creating opportunities to introduce data-driven account targeting, omnichannel engagement, and accelerated product launches in new and existing markets.

Product launches & pipeline Recent and planned launches such as Mytolac (lanreotide) in Germany and AVT06 biosimilar partnerships suggest timing opportunities to collaborate on regulatory submissions, market access strategies, and payer negotiations to maximize uptake across Europe, Canada, and beyond.